Abstract
This work takes advantage of one of the hallmarks of cancer, that is, the presence of tumor infiltrating cells of the immune system and leukocyte‐secreted enzymes, to promote the activation of an anticancer drug at the tumor site. The peptidomimetic integrin ligand cyclo(DKP‐RGD) was found to accumulate on the surface of αvβ3 integrin‐expressing human renal cell carcinoma 786‐O cells. The ligand was conjugated to the anticancer drug paclitaxel through a Asn‐Pro‐Val (NPV) tripeptide linker, which is a substrate of neutrophil‐secreted elastase. In vitro linker cleavage assays and cell antiproliferative experiments demonstrate the efficacy of this tumor‐targeting conjugate, opening the way to potential therapeutic applications.
Funding Information
  • Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2015 project 20157WW5EH)
  • European Commission (MSCA-ITN MAGICBULLET 642004)
  • Università degli Studi di Milano
  • Erasmus+

This publication has 61 references indexed in Scilit: